Baseline Risk Assessment

Before initiating lorlatinib, a thorough assessment of baseline metabolic risk factors is mandatory. This includes, at a minimum, a detailed medical history focusing on prior diagnoses of diabetes, pre-diabetes, or gestational diabetes. While the case report highlights new-onset diabetes in a patient without such history, this doesn't negate the increased risk in individuals with pre-existing conditions. Order a baseline HbA1c and fasting plasma glucose. Note that while guidelines such as the NCCN Guidelines for NSCLC address the management of other toxicities associated with tyrosine kinase inhibitors (TKIs), specific guidance on metabolic monitoring during lorlatinib therapy is lacking. The absence of concrete directives underscores the need for clinicians to proactively manage this potential adverse event.

Monitoring Protocol

Given the rapid onset of DKA observed in the reported case, a frequent monitoring protocol is crucial. I recommend checking fasting blood glucose weekly for the first month, then bi-weekly for the subsequent two months, and then monthly thereafter. HbA1c should be re-evaluated every three months. Patients should be educated on the symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss) and instructed to immediately report any such symptoms. Consider the use of continuous glucose monitoring (CGM) in high-risk patients, if cost and access allow. This aggressive approach is not explicitly mandated by current guidelines, but the potential severity of DKA justifies this proactive strategy. This contrasts with general recommendations for diabetes screening in asymptomatic adults, which are typically less frequent.

When to Consult Endocrinology

Early consultation with an endocrinologist is critical if any of the following occur: fasting plasma glucose > 126 mg/dL, HbA1c > 6.5%, or any symptoms suggestive of hyperglycemia. Do not attempt to manage significant hyperglycemia or DKA independently. Prompt referral ensures appropriate insulin therapy and management of potential complications. Furthermore, endocrinologists can assess for underlying mechanisms contributing to insulin resistance or beta-cell dysfunction induced by lorlatinib. Remember, successful management often requires a multidisciplinary approach.

Algorithm for Lorlatinib-Induced Hyperglycemia

Here’s a simple algorithm that can be incorporated into your practice:

1. Baseline: HbA1c and fasting glucose.
2. If normal, start lorlatinib.
3. Weekly fasting glucose x 1 month, then bi-weekly x 2 months, then monthly. HbA1c q3 months.
4. If fasting glucose > 126 mg/dL or HbA1c > 6.5% or symptomatic hyperglycemia: Consult Endocrinology STAT. Hold lorlatinib pending endocrine evaluation.
5. If DKA suspected: Immediate hospitalization and endocrine consult.

Limitations

This guidance is based on a single case report, which inherently limits its generalizability. Prospective studies are needed to determine the true incidence of lorlatinib-induced diabetes and to validate optimal monitoring strategies. Moreover, the mechanism by which lorlatinib induces hyperglycemia remains unclear, hindering the development of targeted preventive measures. This lack of definitive evidence must be acknowledged. Remember that all recommendations are provisional and subject to revision as new data emerge. We also have to consider the financial toxicity of frequent glucose monitoring. Who will pay for this? Will insurance companies push back?

Conclusion

Lorlatinib is a powerful tool in the treatment of ALK-positive NSCLC, but it is not without risks. New-onset diabetes with DKA is a potentially life-threatening complication that demands proactive management. By implementing a structured monitoring protocol and fostering close collaboration with endocrinology, oncologists can minimize the risk of this adverse event and ensure the best possible outcomes for their patients. This is not merely about following guidelines; it's about practicing vigilant and responsible oncology.